Faruqi & Faruqi, LLP, a national securities law firm, announced an ongoing investigation into Alto Neuroscience, Inc. (NYSE: ANRO). The firm is representing investors who experienced financial losses due to alleged misleading statements made by the company. A securities class action lawsuit has been filed, and a deadline of September 19, 2025, has been set for investors to seek the role of lead plaintiff.
The investigation focuses on Alto‘s statements about the efficacy of ALTO-100, a treatment for major depressive disorder (MDD). The lawsuit alleges that the company misrepresented the drug’s effectiveness in clinical trials. Specifically, the complaint asserts that Alto overstated the drug’s potential and its overall business prospects.
This assertion stems from a press release issued by Alto on October 22, 2024. The release revealed that ALTO-100 failed to meet its primary endpoint in a Phase 2b trial for MDD. This news resulted in a substantial drop in Alto‘s stock price, falling approximately 70%.
Financial analysts quickly responded to the disappointing trial results. One firm lowered its price target for Alto‘s stock significantly, citing concerns about the company’s overall approach to treating central nervous system (CNS) disorders. The firm’s statements implied that the data raised doubts about the efficacy of Alto‘s biomarker approach to CNS disorders and psychiatry.
The lead plaintiff in the class action will be the investor who suffered the largest financial losses and is considered representative of the class. Investors who wish to participate in the lawsuit can file to become the lead plaintiff or choose to remain an absent member of the class. Participation in the lawsuit does not affect an investor’s right to any potential recovery.
Faruqi & Faruqi, LLP encourages anyone with information relevant to the case, including whistleblowers, former employees, and shareholders, to contact the firm. The firm has extensive experience in securities litigation and has recovered hundreds of millions of dollars for investors in past cases. The firm maintains offices in New York, Pennsylvania, California, and Georgia. Investors are advised to contact the firm before the September 19, 2025, deadline to discuss their options. The firm emphasizes that prior results do not guarantee future outcomes.
Related
